Vigil Neuroscience to Present at Guggenheim Healthcare Innovation Conference
05 Novembro 2024 - 9:00AM
Vigil Neuroscience, Inc. (Nasdaq: VIGL), a clinical-stage
biotechnology company committed to harnessing the power of
microglia for the treatment of neurodegenerative diseases, today
announced that management will participate in a fireside chat at
the Guggenheim Healthcare Innovation Conference on November 11,
2024, at 10:30 a.m. ET.
To register for the live webcast, please click
here. The webcast will also be available on the Company’s website
in the “Investors” section under “Events & Presentations.” An
archived webcast will be available for approximately 90 days
following the event. .
About Vigil Neuroscience
Vigil Neuroscience is a clinical-stage
biotechnology company focused on developing treatments for both
rare and common neurodegenerative diseases by restoring the
vigilance of microglia, the sentinel immune cells of the brain.
Vigil is utilizing the tools of modern neuroscience drug
development across multiple therapeutic modalities in its efforts
to develop precision-based therapies to improve the lives of
patients and their families. Iluzanebart, Vigil’s lead clinical
candidate, is a fully human monoclonal antibody agonist targeting
human triggering receptor expressed on myeloid cells 2 (TREM2) in
people with adult-onset leukoencephalopathy with axonal spheroids
and pigmented glia (ALSP), a rare and fatal neurodegenerative
disease. Vigil is also developing VG-3927, a novel small molecule
TREM2 agonist, to treat common neurodegenerative diseases
associated with microglial dysfunction, with an initial focus on
Alzheimer’s disease (AD) patients, including some who carry TREM2
and other disease-associated variants.
Internet Posting of
Information
Vigil Neuroscience routinely posts information
that may be important to investors in the “Investors” section of
its website at https://www.vigilneuro.com. The company encourages
investors and potential investors to consult our website regularly
for important information about Vigil Neuroscience.
Investor Contact:Leah GibsonVice President,
Investor Relations & Corporate CommunicationsVigil
Neuroscience, Inc.lgibson@vigilneuro.com
Media Contact:Megan McGrathCTD Comms,
LLCmegan@ctdcomms.com
Vigil Neuroscience (NASDAQ:VIGL)
Gráfico Histórico do Ativo
De Out 2024 até Nov 2024
Vigil Neuroscience (NASDAQ:VIGL)
Gráfico Histórico do Ativo
De Nov 2023 até Nov 2024
